Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 12:16:2065-2076.
doi: 10.2147/COPD.S275943. eCollection 2021.

Step-Up and Step-Down Treatment Approaches for COPD: A Holistic View of Progressive Therapies

Affiliations
Review

Step-Up and Step-Down Treatment Approaches for COPD: A Holistic View of Progressive Therapies

Jose Luis López-Campos et al. Int J Chron Obstruct Pulmon Dis. .

Abstract

Recent advances in inhaled drugs and a clearer definition of the disease have made the task of managing COPD more complex. Different proposals have been put forward which combine all the available treatments and the different clinical presentations in an effort to select the best therapeutic options for each clinical context. As COPD is a chronic progressive disease, the escalation of therapy has traditionally been considered the most natural way to tackle it. However, the notion of COPD as a constantly progressing disease has recently been challenged and, in specific areas, this points to the possibility of a de-escalation in treatment. In this context, the clinician requires simple, specific recommendations to guide these changes in treatment in their daily clinical practice. To accomplish this, the first step must be a correct evaluation and an accurate initial preliminary diagnosis of the patient's condition. Thereafter, the first escalation in therapy must be introduced with caution as the disease progresses, since clinical trials are not designed with clinical decision-making in mind. During this escalation, three possibilities are open to change the current treatment for a different one within the same family, to increase non-pharmacological interventions or to increase the pharmacological therapies. Beyond that point, a patient with persistent symptoms represents a complex clinical scenario which requires a specialized approach, including the evaluation of different respiratory and non-respiratory comorbidities. Unfortunately, there are few de-escalation studies available, and these are mainly observational in nature. The debate on de-escalation in pharmacological treatment, therefore, involves two main discussion points: the withdrawal of bronchodilators and the withdrawal of inhaled steroids. Altogether, the scheme for modifying treatment must be more personalized than just adding molecules, and the therapeutic response and its conditioning factors should be evaluated at each step before proceeding further.

Keywords: COPD; escalation of treatment; pharmacological therapies; precision medicine.

PubMed Disclaimer

Conflict of interest statement

JLLC has received grants, honoraria during the last 3 years for lecturing, scientific advice, participation in clinical studies or writing for publications for (alphabetical order): AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Esteve, Ferrer, Gebro, GlaxoSmithKline, Grifols, Menarini, Novartis, Rovi, and Teva. The other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Diagnostic possibilities between COPD and asthma.
Figure 2
Figure 2
Initial therapeutic approach for COPD.
Figure 3
Figure 3
Complete escalation scheme for stable COPD.

Similar articles

Cited by

References

    1. Soriano JB, Cosio BG, Lopez-Campos JL, Soler-Cataluna JJ, Ancochea J; en nombre del Comite Cientifico Big C. Chronic obstructive pulmonary disease and big data. Arch Bronconeumol. 2021;57(2):144. doi:10.1016/j.arbres.2020.03.029 - DOI - PubMed
    1. Izquierdo JL, Morena D, Gonzalez Y, et al. Clinical management of COPD in a real-world setting. a big data analysis. Arch Bronconeumol. 2021;57(2):94–100. doi:10.1016/j.arbres.2019.12.025 - DOI - PubMed
    1. Cabrera Lopez C, Gomez Saenz JT, Molina Paris J, Trigueros Carrero JA, Lopez-Campos JL. Enabling a community approach to respiratory diseases: the HACER COPD project. Arch Bronconeumol. 2020. - PubMed
    1. Lopez-Campos JL, Rodriguez DA, Quintana-Gallego E, Martinez-Llorens J, Carrasco Hernandez L, Barreiro E. Ten research questions for improving COPD care in the next decade. COPD. 2019;16(5–6):311–320. doi:10.1080/15412555.2019.1668919 - DOI - PubMed
    1. Halpin DMG, Criner GJ, Papi A, et al. Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;203(1):24–36. doi:10.1164/rccm.202009-3533SO - DOI - PMC - PubMed

MeSH terms

Substances